Gilead Sciences had applied for a patent in Brazil for its Viread medication, which is known to be is a cornerstone drug for AIDS, and the same has been recommended by World Health Organization (WHO). However, the Brazilian patent office has rejected the patent application filed by Gilead as a result of a pre-grant opposition. The rejection of the patent application is believed to provide wider access to this vital drug, as companies in India can make a WHO-approved version for $158 for one patient’s yearly treatment as compared to the $1,387 charged by Gilead in Brazil.

Responding to the rejection, Gilead’s spokesperson has said that this rejection is not the final step, and it is part of the examination procedure. It was further stated that Gilead has been granted patent for its drug in China and United States, among other countries.